| Ajovy |
Fremanezumab-vfrm |
Migraine headaches |
|
|
|
Selected for 2025 subset list |
|
| Austedo; Austedo XR |
Deutetrabenazine |
Chorea in Huntington’s disease, tardive dyskinesia |
Selected for 2025 negotiation |
|
|
|
|
| Basaglar |
Insulin Glargine-yfgn |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Breo Ellipta |
Fluticasone Furoate, Vilanterol |
Asthma, COPD |
Selected for 2025 negotiation |
|
|
|
|
| Cabometyx |
Cabozantinib |
Advanced kidney cancer, neuroendocrine tumors, liver cancer, differentiated thyroid cancer |
|
|
|
|
Selected for 2025 review |
| Calquence |
Acalabrutinib |
Chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma |
Selected for 2025 negotiation |
|
|
|
|
| Cosentyx |
Lxekizumab |
Ankylosing spondylitis, enthesitis-related arthritis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis |
|
Reviewed in 2024 and found unaffordable. Selected for 2025 UPL review. |
|
Selected for 2025 subset list |
|
| Creon |
Pancrelipase (Lipase-Protease-Amylase) |
Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions |
|
|
|
Selected for 2025 subset list |
|
| Dupixent |
Dupilumab |
Asthma and nasal polyps which result in chronic sinusitis, eczema (atopic dermatitis), eosinophilic esophagitis, prurigo nodularis |
|
|
Selected for 2025 review |
|
|
| Eliquis |
Apixaban |
Blood clots |
Selected for 2023-24 negotiation |
|
|
Selected for 2025 subset list |
|
| Emgality |
Galcanezumab |
Migraine headaches |
|
|
|
Selected for 2025 subset list |
|
| Enbrel |
Etanercept |
Psoriasis, psoriatic arthritis/tumor necrosis factor (TNF), rheumatoid arthritis |
Selected for 2023-24 negotiation |
Reviewed in 2024 and found unaffordable. UPL set in 2025. |
|
|
Selected for 2025 review |
| Entresto |
Sacubitril/valsartan |
Heart failure |
Selected for 2023-24 negotiation |
|
|
Selected for 2025 subset list |
|
| Farxiga |
Dapagliflozin |
Chronic kidney disease, diabetes, heart failure |
Selected for 2023-24 negotiation |
|
Reviewed in 2025 and found to pose affordability challenge |
|
|
| Fiasp |
Insulin |
Diabetes |
Selected for 2023-24 negotiation |
|
|
|
|
| Genvoya |
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide |
HIV |
|
Reviewed in 2024 and found NOT unaffordable |
|
|
|
| Humira |
Adalimumab |
Rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS, chronic plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, panuveitis, active polyarticular juvenile idiopathic arthritis |
|
|
|
|
Selected for 2025 review |
| Ibrance |
Palbociclib |
Breast cancer |
Selected for 2025 negotiation |
|
|
|
|
| Imbruvica |
Ibrutinib |
Blood cancers |
Selected for 2023-24 negotiation |
|
|
|
|
| Janumet, Janumet XR |
Sitagliptin, Metformin |
Type 2 diabetes |
Selected for 2025 negotiation |
|
|
|
|
| Januvia |
Sitagliptin |
Diabetes |
Selected for 2023-24 negotiation |
|
|
|
|
| Jardiance |
Eepagliflozin |
Diabetes, heart failure |
Selected for 2023-24 negotiation |
|
Reviewed in 2025 and found to pose affordability challenge |
Selected for 2025 subset list |
|
| Lantus |
Insulin Glargine-yfgn |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Generic |
Insulin Glargine-yfgn |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Lantus SolorStar |
Insulin Glargine |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Linzess |
Linaclotide |
Chronic idiopathic constipation, irritable bowel syndrome with constipation |
Selected for 2025 negotiation |
|
|
|
|
| Mounjaro |
Tirzepatide |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| NovoLog |
Insulin |
Diabetes |
Selected for 2023-24 negotiation |
|
|
|
|
| Nurtec |
Rimegepant, Rimegepant sulfate |
Migraine headaches |
|
|
|
Selected for 2025 subset list |
|
| Ofev |
Nintedanib |
Idiopathic pulmonary fibrosis |
Selected for 2025 negotiation |
|
|
|
|
| Otezla |
Apremilast |
Oral ulcers in Behçet’s Disease, plaque psoriasis, psoriatic arthritis |
Selected for 2025 negotiation |
|
|
|
|
| Ozempic |
Semaglutide |
Type 2 diabetes, type 2 diabetes and cardiovascular disease, obesity/overweight and cardiovascular disease |
Selected for 2025 negotiation |
|
Selected for 2025 review |
Selected for 2025 subset list |
|
| Pomalyst |
Pomalidomide |
Kaposi sarcoma, multiple myeloma |
Selected for 2025 negotiation |
|
|
|
|
| Rybelsus |
Semaglutide |
Type 2 diabetes, type 2 diabetes and cardiovascular disease, obesity/overweight and cardiovascular disease |
Selected for 2025 negotiation |
|
|
Selected for 2025 subset list |
|
| Semglee |
Insulin Glargine-yfgn |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Skyrizi |
Risankizumab |
Crohn’s disease, plaque psoriasis, psoriatic arthritis |
|
|
Selected for 2025 review |
|
|
| Stelara |
Ustekinumab |
Crohn’s disease, plaque psoriasis, psoriatic arthritis, ulcerative colitis |
Selected for 2023-24 negotiation |
Reviewed in 2024 and found unaffordable. Selected for 2025 UPL review. |
|
|
|
| Toujeo Max SolorStar |
Insulin Glargine-yfgn |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Toujeo SolorStar |
Insulin Glargine-yfgn |
Diabetes |
|
|
|
Selected for 2025 subset list |
|
| Tradjenta |
Linagliptin |
Type 2 diabetes |
Selected for 2025 negotiation |
|
|
|
|
| Trelegy Ellipta |
Fluticasone Furoate, Vilanterol |
Asthma, COPD |
Selected for 2025 negotiation |
|
|
Selected for 2025 subset list |
|
| Trikafta |
Eeexacaftor, Tezacaftor, Ivacaftor |
Cystic fibrosis |
|
Reviewed in 2023 and found NOT unaffordable |
|
|
|
| Trulicity |
Dulaglutide |
Glycemic control in type 2 diabetes mellitus, reduce the risk of major adverse cardiovascular events in type 2 diabetes mellitus |
|
|
Selected for 2025 review |
Selected for 2025 subset list |
|
| Ubrelvy |
Ubrogepant |
Migraine headaches |
|
|
|
Selected for 2025 subset list |
|
| Vraylar |
Rariprazine |
Bipolar I disorder,major depressive disorder, schizophrenia |
Selected for 2025 negotiation |
|
|
Selected for 2025 subset list |
|
| Wegovy |
Semaglutide |
Type 2 diabetes, type 2 diabetes and cardiovascular disease, obesity/overweight and cardiovascular disease |
Selected for 2025 negotiation |
|
|
|
|
| Xarelto |
Rivaroxaban |
Blood clots, coronary or peripheral artery disease |
Selected for 2023-24 negotiation |
|
|
Selected for 2025 subset list |
|
| Xifaxan |
Rifaximin |
Hepatic encephalopathy, irritable bowel syndrome with diarrhea |
Selected for 2025 negotiation |
|
|
|
|
| Xtandi |
Enzalutamide |
Prostate cancer |
Selected for 2025 negotiation |
|
|
|
Selected for 2025 review |
